Smith & Nephew ADR had its Relative Strength (RS) Rating upgraded from 69 to 79 Monday — a welcome improvement, but still shy of the 80 or better score you look for.
This unique rating measures market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the trailing 52 weeks stacks up against all the other stocks in our database.
History shows that the best-performing stocks typically have an RS Rating north of 80 as they launch their largest price moves. See if Smith & Nephew ADR can continue to rebound and clear that threshold.
How To Invest In Stocks In Both Bull And Bear Markets
Smith & Nephew ADR is building a consolidation with a 31.72 buy point. See if it can clear the breakout price in heavy trading.
Smith & Nephew ADR showed -2% EPS growth in its most recent report. Revenue gains came in at 6%. Look for the next report on or around Apr. 30.
Smith & Nephew ADR holds the No. 21 rank among its peers in the Medical-Products industry group. Boston Scientific, Pro-Dex and Axogen are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
